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Abstract
Pancreatic ductal adenocarcinoma (PDAC) remains
an important cause of malignancy-related death and is
the eighth most common cancer with the lowest
overall 5-year relative survival rate. To identify new
molecular markers and candidates for new therapeutic
regimens, we investigated the gene expression profile
of microdissected cells from 11 normal pancreatic
ducts, 14 samples of PDAC, and 4 well-characterized
pancreatic cancer cell lines using the Affymetrix U133
GeneChip set. RNA was extracted from microdis-
sected samples and cell lines, amplified, and labeled
using a repetitive in vitro transcription protocol.
Differentially expressed genes were identified using
the significance analysis of microarrays program. We
found 616 differentially expressed genes. Within these,
140 were also identified in PDAC by others, such as
Galectin-1, Galectin-3, and MT-SP2. We validated the
differential expression of several genes (e.g., CENPF,
MCM2, MCM7, RAMP, IRAK1, and PTTG1) in PDAC
by immunohistochemistry and reverse transcription
polymerase chain reaction. We present a whole ge-
nome expression study of microdissected tissues from
PDAC, from microdissected normal ductal pancreatic
cells and pancreatic cancer cell lines using high-
density microarrays. Within the panel of genes, we
identified novel differentially expressed genes, which
have not been associated with the pathogenesis of
PDAC before.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is an important
cause of malignancy-related deaths. In the United States, it
ranks fifth among the leading causes of cancer death,
accounting for approximately 30,000 deaths annually [1]. Apart
from surgery, there is no effective therapy; but even most of
the resected patients usually die within 1 year postoperatively.
In the past years, several cancer-related genes have been iden-
tified in PDAC. The most frequently affected are K-ras, DPC4,
p53, and p16 [2–5], all of which appear to play a role in the
development of PDAC. However, considering the complexity of
the genome, it is most likely that most of the molecular changes
causing pancreatic cancer still need to be elucidated [6].
Recently, DNA microarray technology has been applied to
a number of tumors of, for example, the breast [7], colon
[8], prostate [9], esophagus [10], stomach [11], and pancreas
[12–17]. These studies generated large sets of new class II
cancer genes revealing dysregulation at the level of gene
expression [18]. However, most of these studies were per-
formed on whole tissue samples or cell lines. In cell lines,
in vitro conditions may induce changes in gene expression
that are not present in vivo. PDAC specimens contain dif-
ferent cell types, including ductal, acinar, islet, inflammatory,
and nerve cells, and fibrocystic elements. When whole tissues
are used in such studies, expression profiles may represent
both the tumor and the adjacent non-neoplastic tissue. There-
fore, microdissection is the method of choice to generate a
true picture of gene expression changes [19]. Improvement in
the array technology made it possible to examine virtually every
gene at single gene level by expression profiling. In this study,
we used microdissected tumor tissue and microdissected
normal ductal epithelium for RNA extraction and subsequent
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analysis using the Affymetrix U133 set (GeneChips A and B;
Affymetrix, Santa Clara, CA), which contains 45,000 frag-
ments corresponding to 33,000 known genes and 6000
expressed sequence tags (ESTs), and therefore approxi-
mately the whole genome.
We identified genes whose expression levels differed
significantly between malignant and benign pancreatic cells
of the ductal phenotype to generate a set of genes that may
be used as diagnostic markers or as targets for new thera-
peutic approaches. Furthermore, we validated genes of this
set to prove the appropriateness of our approach.
Materials and Methods
Patients and Tissues
Freshly frozen tissue samples of PDAC (n = 14) were
obtained from surgical specimens from patients who were
operated at the Department of Visceral, Thoracic, and Vas-
cular Surgery, University Hospital Carl Gustav Carus, Tech-
nical University of Dresden (Dresden, Germany) and the
Department of General Surgery, University of Kiel (Kiel,
Germany) between 1996 and 2003. The clinical data of these
patients are shown in Table 1. Normal pancreatic tissue was
obtained from 11 patients who underwent pancreatic resec-
tion for other pancreatic diseases. These tissues were
histologically normal tissues with no visible dysplastic
changes in the ducts and were taken from the distal parts
of the resected pancreas. Prior to surgery, all patients had
given informed consent, which had been approved by the
local ethics committee. Immediately after surgical removal,
the specimens were sectioned and microscopically evaluat-
ed. Suitable samples of tumor tissue or normal tissue were
snap frozen in liquid nitrogen and stored at 80jC until
further processing.
Microdissection
Frozen tissue specimens were cut into 10-mm-thick sec-
tions and immediately fixed on slides in 70% ethanol. The
sections were briefly stained with hematoxylin and eosin
(H&E), and coverslipped. Suitable areas for microdissection
were marked on these slides serving as a template. The
tissue blocks were serially cut to 5-mm-thin sections, briefly
fixed in 70% RNase-free ethanol, and stained with H&E.
PDAC cells and normal ductal cells were dissected manually
using a sterile injection needle (Figure 1). The estimated
cellularity was 10,000 to 11,000 cells per microdissected
sample. The cellularity of the dissections was approximately
95%. These cells were pooled in ice-cooled guanadine
thiocyanate (GTC) buffer (Promega, Heidelberg, Germany)
for further RNA preparation.
Cell Culture
The pancreatic cell lines Colo357, PancTUI, PT45,
Panc89, CAPAN2, HPAF-II, BxPC3, CAPAN1, PaCa44,
CFPAC-1, PT64, PT89, PT96, PT115, PT101, PT103,
R89, ASPC1, MiaPaCa2, and Panc1 were cultured in RPMI
1640 supplemented with 10% fetal bovine serum, 2 mM
glutamine, nonessential amino acids (5 ml/l), penicillin
(10,000 U/ml), and streptomycin (10 mg/ml), and passaged
before they reached confluency. All cell culture materials
were obtained from Invitrogen (Karlsruhe, Germany).
RNA Preparation and Array Hybridization
Poly A+ RNA from the microdissected surgical specimens
and cell cultures was prepared using the PolyATtract 1000 kit
(Promega) according to the manufacturer’s recommenda-
tions. For each sample, cDNA synthesis and repetitive
in vitro transcription were performed three times, as de-
scribed previously [15]. In brief, first-strand cDNA synthesis
was initiated using the Affymetrix T7-oligo-dT promoter–
primer combination at 0.1 mM. The second-strand cDNA
synthesis was generated with internal priming. In vitro tran-
scription was performed using Ambion’s Megascript kit
(Ambion, Huntington, UK), as recommended by the manu-
facturer. From the generated aRNA, a new first-strand
synthesis was initiated using 0.025mM of a random hexamer
as primer. After completion, the second-strand synthesis
was performed using the Affymetrix T7-oligo-dT promoter–
primer combination as primer at a concentration of 0.1 mM.
A second in vitro transcription was performed and then
the procedure was repeated one additional time. During
the last in vitro transcription, biotin-labeled nucleotides were
Table 1. Clinicopathologic Data of 14 Patients with PDAC.
Code Origin Gender Age (years) Histology T N M Grading
PDT14 Dresden Female 57 PDAC, liver metastasis X X 1 X
PT10 Dresden Female 62 PDAC 3 1b 0 2
PT55 Dresden Male 66 PDAC with anaplastic component 3 1b 0 3
39B Dresden Male 59 PDAC 2 0 0 2
33B Dresden Female 73 PDAC 3 1b 0 3
35B Dresden Male 74 PDAC 2 0 0 3
56A Dresden Female 71 PDAC 3 1a 0 3
PDT12 Dresden Female 74 PDAC 3 1b 0 1
PDT9 Dresden Male 67 PDAC, liver metastasis X X 1 2
PDT5 Dresden Male 61 PDAC, liver metastasis X X 1 3
PT44 Dresden Male 64 PDAC involving ampulla of Vater 3 0 0 3
PKT5 Kiel Female 69 PDAC 3 1 0 2
PKT9 Kiel Male 71 PDAC 3 1 0 3
PKT4 Kiel Female 66 PDAC 3 1 0 2
X: at time of operation.
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incorporated into the aRNA, as recommended by the Affy-
metrix protocol. RNA amplification after each round of
amplification was 50 to 100, and the correlation coefficient
of gene expression profiles between the starting RNA and
the amplified RNA is 0.77 to 0.79 [20]. Hybridization and
detection of the labeled aRNA on the U133 A/B Affymetrix
GeneChip set were performed according to Affymetrix’s
instructions.
Chip Design and Bioinformatics Analysis
The U133 A/B Affymetrix GeneChip set used in this study
consists of more than 44,000 probe sets resembling roughly
33,000 genes and 6000 ESTs. The Cel Files obtained from
the Affymetrix MAS 5.0 software were used for further
analysis. The files were loaded into dChip 1.3 (http://
www.dchip.org) then normalized, and expression values as
well as absolute calls were calculated using the PM/MM
model [21]. The expression values and absolute calls were
exported and further explored using SAM (http://www-stat.
stanford.edu/ftibs/SAM/) [22] and Excel (Microsoft, Red-
mond, WA). We scored genes as differentially expressed
if they met the following criteria: a fold change > 2 and a
q value < 15%, or presence call in at least of 60% of one
tissue type but not within the other type (Figure 2).
To identify signature genes, normalized gene expression
values were loaded into Genecluster2 (http://www-genome.
wi.mit.edu/cancer/software/genecluster2/gc2.html) [23].
Low expression values were floored to 10 and only those
probesets fulfilling the criteria of Max/Min > 3 and MaxMin
> 200 were used. Signature genes were identified using the
K-nearest neighbor (KNN) method with a leave-one-out
(LOO) validation step. Hierarchical clustering was performed
using dChip (Figure 2).
Reverse Transcription Polymerase Chain Reaction (RT-PCR)
RNA from normal pancreatic tissue and pancreatic tumor
tissue was isolated using the ‘‘Micro to Mini Total RNA
Purification Kit’’ (Invitrogen) according to the manufacturer’s
procedure. Reverse transcription using random hexamers
and ‘‘Superscript’’ reverse transcriptase (Invitrogen) followed
by PCR amplification (58jC annealing temperature,
27 cycles) was performed under standard PCR conditions.
Figure 1. Manual microdissection of pancreatic tissue. Left: Before microdissection; right: after microdissection; upper panel: pancreatic ductal adenocarcinoma;
lower panel: normal ductal epithelia.
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Figure 2. Analysis of gene expression in PDAC. (A) Hierarchical clustering of 14 microdissected PDACs, 11 microdissected normal ductal cells, and 4 established
pancreatic tumor cell lines using the 616 differential gene set and a Euclidian distance matrix. The different colors reflect the predominant expression of the genes
(green: normal tissue; blue: cell lines and PDAC; red: PDAC). The individual samples are colored (green: normal; blue: cell lines; red: PDAC). (B) Heat map of
signature genes in PDAC. Genes were identified using the KNN method with a LOO validation step. (C) Heat map of protein kinase expression found in the set of
differentially expressed genes. Genes that are upregulated appear in red, and those that are downregulated appear in green, with the expression value reflected by
the intensity of the color.
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Primers for PCR amplification were synthesized (MWG-
Biotech, Ebersberg, Germany) (Table 2). PCR products
were separated by agarose gel electrophoresis and visual-
ized by ethidium bromide staining.
Total RNA from the pancreatic cell lines was isolated
using the RNeasy RNA isolation kit (Qiagen, Hilden,
Germany) and transcribed into cDNA as described above.
Quantitative PCR detection was applied using an ABI Se-
quence Detection System 7700 and the Sybr Green Master
Mix (ABI, Weiterstadt, Germany) according to the manufac-
turer’s recommendation.
Immunohistochemistry
For immunohistochemistry, 10 cases of PDAC were
randomly selected and 5-mm-thin sections were prepared.
Mouse monoclonal antibodies against human CENPF (clone
D8; Abcam Ltd., Cambridge, UK), human MCM2 (clone
CRCT2; Novocastra, Newcastle, UK), and human MCM7
(clone CRCT7; Novocastra) were stained with the ABC
method as described previously [24]. The staining intensity
was semiquantitatively assessed using a cutoff point of more
than 10% positive cells with either cytoplasmic or nuclear
staining. The staining intensity was recorded as weak or
strong. Normal pancreatic parenchyma was also screened
for the presence of protein expression in acinar, ductal, and
endocrine cells.
Results
Using microdissection, tissues from 14 patients with PDAC
and normal ductal epithelia from 11 patients were obtained.
Gene expression profiles of these tissues were acquired
and compared.
The combination of fold change (cutoff: two-fold), SAM q
value (cutoff < 15%), and absolute call (cutoff: present in
at least 60% of one tissue type, absent in the other) analysis
yielded a total of 616 differentially expressed genes. Overall,
204 genes were underexpressed and 412 were overex-
pressed in PDAC compared to microdissected normal ductal
cells. In Table 3, all genes with a fold change of 3 or more
and a q value < 5% (118 in total, 66 overexpressed and
52 underexpressed) are shown. Hierarchical clustering
using this set of genes of the samples revealed three distinct
clusters of primary tumors, benign tissues, and cell lines
showing the diversity between primary tissue samples and
established cell lines (Figure 2A).
We applied KNN analysis with LOO validation to identify
pancreatic cancer signature genes. We detected a set of 104
probesets, which enabled us to discriminate between tumor
tissue and normal tissue with a specificity of 73% (three
normal tissues within the tumor group) and a sensitivity of
93% (one tumor tissue within the normal group; Figure 2B).
Analysis of the differentially expressed genes using the
Geneontology system of molecular function (http://www.
geneontology.org) revealed several distinct groups (data
not shown). Interestingly, 23 of 616 genes were grouped
into the family of protein kinases (Figure 2C). Of these,
19 were overexpressed in PDAC, whereas four were under-
expressed. Within the group of overexpressed protein
kinases, we identified STK6 (STK15/Aurora), which already
has been reported by others [25], and IRAK1, an inducer of
NF-nB [26]. Moreover, the protein kinase KIT that is impli-
cated in the development of gastrointestinal stromal tumors
was found to be downregulated in PDAC. This implies that
KIT, in contrast to STK6/STK15, might not be a target in
PDAC therapy.
Comparison of Expression Data
To interpret our results in a general context, we analyzed
the data already published on the 616 genes. We found that
163 of 616 genes already have been reported by other
groups, which analyzed PDAC with microarrays (Table 3).
One hundred four of the upregulated genes in our set have
been reported before. Among them was S100P, which has
been found in seven independent experiments. Fifty-nine
from the downregulated genes of the set have been found in
other expression profiling experiments. Among them were
GATM and KLK1, which have been found in four and three
other investigations, respectively. No discrepant finding
concerning the direction of differential expression between
our results and those of others has been found.
Table 2. Primer and Probe Sequences Used for the Verification of Differential Expression.
Gene Sense 5V–3V Antisense 5V–3V
GAPDH CCAGCCGAGCCACATCGCTC ATGAGCCCCAGCCTTCTCCAT
G6PD ACGTGATGCAGAACCACCTACTG ACGACGGCTGCAAAAGTGGCG
CCNB1 GATATCTATCAGTATCTCAGGCAGCTG ATACTTGGAAGCCAAGAGCAGAGC
CCNB2 GATATCTATCAGTATCTCAGGCAGCTG ATACTTGGAAGCCAAGAGCAGAGC
CENPF GCGGCAGAAAAGAAACAGAC TCTTCTGTGTCGATGCCAAG
CFLAR ATGGACAGAAAAGCTGTGGAG CTTCAGGTCTATTCTGTGGATG
EFNB2 CTGCTGGATCAACCAGGAAT CTGTTGCCGTCTGTGCTAGA
HOXC6 ACAGACCTCAATCGCTCAGG GGTACCGCGAGTAGATCTGG
LOXL2 CAGACCACCTACCTGGAGGA GTTGTGGATCTGGGAGGAGA
MADD TGTGCAGGACCTGAAGACTG ACAAAGACGCCTCGAACTGT
osf-2 TGCATTATTCACAGGTGCCAG ACTCTCCAGTGTTCTGAGTC
PTTG1 AAGGAAAATGGAGAACCAGGC GCTTGGCTGTTTTTGTTTGAGG
RAMP ACAGCAGCAGGTGATCAAACAGC GAAGGAGCAGAGTCCTTTTGAATTCTG
PLAG1 TTTCCTTGCCAACTGTGTGAC CTTTGTTAGGGTCGTGTGTATG
ECT2 ACTAGCTTGGCAGACTCTTC ATCCTGAAAGTCCGTGACTAC
UP CGGAAAACGGACCTTAACAA GATACGCCTGCTTGTCCTTC
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Table 3. Differentially Expressed Genes in Microdissected PDAC and Microdissected Normal Ductal Cells Using High-Density Microarrays.
Affymetrix ID Unigene ID Gene Symbol Fold Change Reference PDAC Reference Cancer N Array T Array Reference Array in PDAC
(A) Upregulated genes
218741_at Hs.208912 MGC861 18.15 0 0
218542_at Hs.14559 C10orf3 9.03 0 2 [17,31]
208511_at Hs.350968 PTTG3 8.41 X 0 0
203454_s_at Hs.279910 ATOX1 8.13 0 0
202478_at Hs.155418 GS3955 7.86 0 1 [17]
203819_s_at Hs.79440 KOC1 7.42 X X 0 2 [16,31]
221521_s_at Hs.433180 PSF2 6.97 0 0
205909_at Hs.99185 POLE2 6.59 0 0
200755_s_at Hs.7753 CALU 5.53 0 0
204170_s_at Hs.83758 CKS2 5.45 X 0 4 [15,17,32,37]
212398_at Hs.263671 RDX 5.24 X 0 0
204822_at Hs.169840 TTK 5.18 X 0 0
209642_at Hs.98658 BUB1 5.17 X X 0 0
210052_s_at Hs.9329 C20orf1 4.91 X 0 0
202107_s_at Hs.57101 MCM2 4.83 X 0 0
209172_s_at Hs.77204 CENPF 4.77 X 0 0
203108_at Hs.194691 RAI3 4.74 X 0 5 [14–17,31]
201467_s_at Hs.406515 NQO1 4.69 X 0 3 [17,37,38]
218960_at Hs.63325 TMPRSS4 4.64 0 0
208932_at Hs.2903 PPP4C 4.54 0 0
214710_s_at Hs.23960 CCNB1 4.46 X 0 1 [16]
212992_at Hs.57548 LOC113146 4.42 0 0
208079_s_at Hs.250822 STK6 4.38 X 0 2 [15,32]
208002_s_at Hs.8679 BACH 4.27 0 0
201890_at Hs.75319 RRM2 4.24 X 0 0
218886_at Hs.52256 FLJ20624 4.24 0 0
206074_s_at Hs.57301 HMGA1 4.11 X X 0 1 [32]
203764_at Hs.77695 DLG7 4.01 0 0
207165_at Hs.72550 HMMR 3.98 X X 0 0
204507_s_at Hs.278540 PPP3R1 3.86 0 0
218585_s_at Hs.126774 RAMP 3.79 X 0 0
219148_at Hs.104741 TOPK 3.68 X 0 0
201292_at Hs.156346 TOP2A 3.68 X 0 2 [16,31]
202589_at Hs.29475 TYMS 3.65 X 0 0
209405_s_at Hs.289108 FAM3A 3.61 0 0
206858_s_at Hs.820 HOXC6 3.55 X 0 0
203213_at Hs.334562 CDC2 3.52 X X 0 2 [14,16]
220060_s_at Hs.121553 FLJ20641 3.48 0 0
202784_s_at Hs.18136 NNT 3.43 0 0
203939_at Hs.153952 NT5E 3.38 0 0
205167_s_at Hs.656 CDC25C 3.36 X 0 0
204026_s_at Hs.42650 ZWINT 3.34 0 0
220658_s_at Hs.222024 ARNTL2 3.31 0 2 [16,31]
203234_at Hs.77573 UP 3.31 0 0
210809_s_at Hs.136348 osf-2 3.31 X 0 3 [13,31,37]
202998_s_at Hs.83354 LOXL2 3.28 X 0 1 [17]
203878_s_at Hs.155324 MMP11 3.28 X 0 2 [13,16]
204962_s_at Hs.1594 CENPA 3.25 0 0
202668_at Hs.30942 EFNB2 3.25 X 0 0
201195_s_at Hs.184601 SLC7A5 3.13 X 0 1 [31]
204351_at Hs.2962 S100P 3.12 X X 0 7 [13,14,16,17,31,37,38]
202705_at Hs.194698 CCNB2 3.07 X 0 0
201850_at Hs.82422 CAPG 3.05 0 3 [14,16,31]
205081_at Hs.423190 CRIP1 3.02 X 0 1 [13]
200085_s_at Hs.172772 TCEB2 3.02 0 0
204825_at Hs.184339 MELK 3 0 0
202870_s_at Hs.82906 CDC20 Only in T X X 0 2 [15,17]
203596_s_at Hs.27610 RI58 Only in T X 0 0
203870_at Hs.109268 FLJ12552 Only in T 0 0
204948_s_at Hs.9914 FST Only in T X 0 0
205653_at Hs.100764 CTSG Only in T 0 0
210252_s_at Hs.82548 MADD Only in T X 0 0
218355_at Hs.279766 KIF4A Only in T 0 0
218663_at Hs.193602 HCAP-G Only in T X 0 0
219182_at Hs.6853 FLJ22167 Only in T 0 0
49452_at Hs.234898 EST Only in T 0 0
(B) Downregulated genes
225016_at Hs.374481 DRAPC1 0.1 X 1 0 [17]
206464_at Hs.27372 BMX 0.1 X 1 0 [17]
continued on next page
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Interestingly, the majority of genes (453 of 616) was not
reported by other groups, possibly showing the advantages
of the microdissection approach. This is especially true for
genes that are downregulated in PDAC because of the
composition of normal pancreatic tissue where the ductal
epithelia comprise only around 5% of the cells.
Verification of Differential Expression
From the 616 differentially expressed genes, we selected
several for further validation by immunohistochemistry and/
or RT-PCR. We found that for the majority of genes, the
differential expression could be confirmed by another
method. Immunohistochemical analysis revealed that
CENPF as well as MCM2 and MCM7 were expressed in
9 of 10 PDACs with mainly strong nuclear expression (Table
4, Figure 3), whereas the normal pancreas lacked specific
reactions. In particular, normal duct epithelia, as well as
acinar cells, were unreactive.
For RT-PCR analysis, 9 normal tissues and 13 tissues
from PDAC (nine of them as corresponding pairs) from
individual tumors have been investigated for expression of
the selected genes (Figure 4, A and B). Out of 62 PCR
Affymetrix ID Unigene ID Gene Symbol Fold Change Reference PDAC Reference Cancer N Array T Array Reference Array in PDAC
220275_at Hs.114648 ERG-1 0.1 0 0
217452_s_at Hs.181353 B3GALT2 0.1 0 0
206131_at Hs.1340 CLPS 0.04 3 0 [15,17,37]
205910_s_at Hs.406160 CEL 0.04 1 0 [37]
206827_s_at Hs.302740 TRPV6 0.04 X 0 0
210168_at Hs.1282 C6 0.04 X 1 0 [13]
205971_s_at Hs.74502 CTRB1 0.07 X 1 0 [15]
207077_at Hs.169234 ELA2B 0.07 1 0 [13]
205719_s_at Hs.1870 PAH 0.08 0 0
206694_at Hs.73923 PNLIPRP1 0.08 X 1 0 [37]
216687_x_at Hs.150207 UGT2B15 0.09 X 0 0
203924_at Hs.89552 GSTA1 0.09 X 1 0 [13]
206297_at Hs.8709 CTRC 0.09 0 0
206212_at Hs.89717 CPA2 0.11 2 0 [17,37]
206446_s_at Hs.21 ELA2A 0.11 1 0 [17]
210080_x_at Hs.181289 ELA3A 0.12 0 0
213071_at Hs.80552 DPT 0.12 0 0
206311_s_at Hs.992 PLA2G1B 0.13 X X 2 0 [13], [15]
219564_at Hs.50151 KCNJ16 0.14 0 0
210262_at Hs.2042 TPX1 0.14 0 0
207636_at Hs.158308 SERPINI2 0.14 X X 0 0
216699_s_at Hs.123107 KLK1 0.14 X 3 0 [37], [19]
215563_s_at Hs.278657 MSTP9 0.15 0 0
214324_at Hs.53985 GP2 0.16 1 0 [37]
211738_x_at Hs.425790 ELA3B 0.16 0 0
208498_s_at Hs.274376 AMY1A 0.17 X 0 0
205771_s_at Hs.12835 AKAP7 0.18 0 0
205869_at Hs.241395 PRSS1 0.18 X 0 0
205912_at Hs.102876 PNLIP 0.19 2 0 [17,37]
208450_at Hs.113987 LGALS2 0.19 X 2 0 [13,17]
205509_at Hs.180884 CPB1 0.19 0 0
211766_s_at Hs.143113 PNLIPRP2 0.19 0 0
229963_at Hs.47209 EST 0.19 0 0
207434_s_at Hs.19520 FXYD2 0.19 1 0 [13]
205799_s_at Hs.239106 SLC3A1 0.21 0 0
205923_at Hs.12246 RELN 0.22 X 0 0
206262_at Hs.2523 ADH1C 0.23 X 1 0 [17]
206610_s_at Hs.1430 F11 0.23 0 0
205363_at Hs.9667 BBOX1 0.23 0 0
203908_at Hs.5462 SLC4A4 0.25 2 0 [13,17]
204359_at Hs.48998 FLRT2 0.25 X 0 0
213436_at Hs.75110 CNR1 0.27 X 0 0
205380_at Hs.15456 PDZK1 0.29 X 1 0 [17]
206204_at Hs.83070 GRB14 0.29 X 0 0
244402_at Hs.110 KIAA0436 0.31 0 0
206010_at Hs.241363 HABP2 0.32 X 2 0 [37]
208741_at Hs.23964 SAP18 Only in N X 0 0
209773_s_at Hs.75319 RRM2 Only in N X 0 0
214373_at Hs.356686 PPP4R2 Only in N 0 0
235132_at Hs.296995 EST Only in N 0 0
Differentially expressed genes with their Unigene Cluster ID, gene symbol, fold change tumor/normal, and references concerning the stated differential expression
in previous expression profiling experiments in PDAC [13–17,31,32,37–39].
CF T/N: the change folds of the mean expression values of 14 microdissected PDAC against the mean of 11 microdissected normal pancreatic ductal tissues.
N array: overexpressed in the normal pancreatic tissue in the specified paper.
T array: overexpressed in PDAC in the specified paper.
X: a reference found January 2004 in PubMed database. Only genes with a fold change of at least three are included in the table.
Table 3. Continued
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reactions from the normal/tumor tissue pairs, 51 reactions
showed an upregulation of gene expression in tumor tissues
when compared to normal tissues, whereas 11 PCR reac-
tions did not show this outcome. This is because not all
individual tumor samples showed an upregulation of the
tested gene transcripts, whereas others did. Although some
genes are clearly upregulated in virtually every tumor sample
(e.g., RAMP), other ones are not (e.g., CCNB2). These
results confirm our approach. However, it indicates the fact
that gene expression is heterogeneous within tumors. This is
also underlined by our observation that genes identified by
gene expression profiling are heterogeneously expressed in
analyzed cell lines, such as LOXL2, which is expressed
mainly in the primary cell lines. We also found a high
expression of IRAK1 in all cell lines tested (Figure 4B).
In parallel to RT-PCR, we performed Western blot anal-
ysis with three corresponding normal/tumor tissue pairs to
investigate the expression pattern of CCNB1 (cyclin B1) and
CDC25B. Although the expression intensity between the
tested samples varied, an upregulation of both proteins in
tumor tissues was verifiable, except in one sample with
comparable expression (data not shown).
Discussion
Using the Affymetrix U133 GeneChip set, we performed a
whole genome gene expression analysis of microdissected
cells of PDAC and microdissected normal ductal epithelia of
the pancreas. Because the stromal portion in PDAC often
exceeds that of neoplastic cells, we carefully microdissected
the tumor tissue, employing manual microdissection, and
obtained highly homogeneous cell compartments. The
same holds true for the dissection of normal pancreatic duct
cells, which were selectively removed from large-sized and
Figure 3. Immunohistochemical analysis of differentially expressed genes found in PDAC by microarray analysis. CENPF (A–C), MCM7 (D–F), and MCM2 (G– I)
are highly expressed in the nucleus of PDACs of different grades (D: G1; A and E: G2; B, C, and F: G3; C, F, and I: normal pancreas). Original magnification, 100
(A, D, and E). Original magnification, 200 (C). Original magnification, 400 (B and F).
Table 4. Results of Immunohistochemical Stainings in PDAC.
Gene
Product
PDAC
Nuclear
PDAC
Cytoplasmic
Normal
Duct Cells
Acinar
Cells
Endocrine
Cells
CENPF 9/10 2/10 0/10 1/10 0/10
MCM2 7/10 1/10 1/10 0/10 0/10
MCM7 9/10 0/10 1/10 5/10 1/10
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Figure 4. Validation of differentially expressed genes using RT-PCR. (A) RT-PCR analysis of five genes. RNA from tumor (T) and corresponding normal tissue (N)
from four patients with a PDAC was isolated, and RT-PCR analysis for G6PD (control), PLAG1, PTTG, osf-2, and RAMP1 was performed. PCR products were
separated by agarose gel electrophoresis and visualized by ethidium bromide staining. (B) Overview of RT-PCR results from normal pancreatic tissue, PDAC
(upper panel), and cell lines (lower panel). GAPDH and G6PD expression analysis served as control. White background: not determined; green: no PCR signal (),
cT value > 35; yellow: PCR signal visible (/+); orange: clear PCR signal (+), cT value > 27< 35; red: strong PCR signal (++), cT value > 20 < 27; dark red: very
strong RT-PCR signal (+++), cT value < 20.
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medium-sized ducts. The fact that there is a need to distin-
guish neoplastic from non-neoplastic tissues is shown by
studies on prostate carcinomas comparing the differential
gene expression in dissected and nondissected tissues. Of
the differential genes identified in microdissected tissues,
only one third was also found in bulk tissues [27]. Generally,
microdissection results in smaller amounts of poly A+ RNA.
We therefore applied a linear amplification protocol with
minimal bias as already described by us and other groups
[20,28].
We compared the obtained gene expression profiles with
each other as well as with the expression profiles of pancre-
atic cancer cell lines, and we identified 616 differentially
expressed genes. We found 412 to be upregulated and
204 genes to be downregulated in PDAC. A number of these
genes were already reported by other groups, which con-
ducted global gene expression studies in PDAC
[12,14,16,29–36]. However, we also identified additional
genes that have not yet been found to be differentially
expressed in pancreatic cancer but were already identified
within other malignancies. The third and largest group of
genes consists of genes that have not been associated with
any type of carcinoma so far.
Comparing our results with other studies employing large-
scale gene expression analysis of PDAC using DNA micro-
arrays [13–16,31,32,37–39], we found that only a few genes
were shown to be differentially expressed in more than one
study (Table 3). There are several potential reasons for the
low concordance of these studies. First, the type, histology,
and number of samples used (i.e., established cell lines or
primary tissue) differed. This could be even more important
for the type of normal tissue used (commercially available
RNA, normal tissue from resected pancreatic tumors, or
donor organs). Second, microdissection for large-scale gene
expression analysis was applied only by two groups [15,17].
Third, different arrays and array technologies may lead to
different gene expression results [40]. Fourth, there is no
common standard to assign differential expression within a
gene expression profiling experiment. Furthermore, there
are different implementations of standard techniques leading
to different results. For these reasons, the results of expres-
sion profiling studies are intrinsic, subjective, and not easily
comparable. However, all these studies lead to sets of
candidate genes for further investigations as potential
markers and/or therapeutic targets.
From the genes that were overexpressed in PDAC, we
chose CCNB1, CCNB2, CDC25B, CENPF, CFLAR, MCM2,
MCM7, PLAG1, ECT2, PTTG1, osf-2, and RAMP for valida-
tion.CDC25B,CCNB1,CCNB2,CENPF,MCM2, andMCM7
are involved in cell cycle regulation. CCNB1 (cyclin B1)
complexes with CDC2 (cell division cycle 2) and is important
during G2/M phase transition. CCNB1 overexpression was
significantly correlated with tumor size, stage, and survival of
patients with laryngeal squamous cell carcinoma [41]. An
overexpression of cyclins B1 and B2, which may play a key
role in transforming growth factor b–mediated cell cycle
control, was also found in colorectal cancers and other
tumors [42]. The cell division cycle 25B protein (CDC25B)
belongs to phosphatases and activates CDC2 by removing
phosphate groups. This step is necessary for entry into
mitosis. Recently, it could be demonstrated by others that
CDC25B is overexpressed in pancreatic carcinomas and
their metastases. Interestingly, treatment with CDC25B
inhibitors caused a growth reduction of pancreatic cancer
cell lines [43]. MCM2 and MCM7 are both involved in
initiation replication. Evidence suggests that MCM7 acts as
a cofactor for oncogenic transformation [44], whereasMCM2
is a biomarker of proliferating cells independently of the p53
status [45]. These differentially expressed genes underline
the fact that pancreatic cancer is highlighted by an intense
proliferation. However, we identified also other genes in-
volved in the signal transduction of several pathways.
For the first time, we report here the overexpression of the
pituitary tumor transforming gene 1 (PTTG1) in pancreatic
cancer. PTTG1 is expressed at very low levels in normal
tissues, except for few cell types such as spermatocytes and
spermatids. Overexpression of PTTG1 has been demon-
strated in breast and other tumors [46–48]. It is a potent
oncogene because of its ability to complex with p53 and thus
to prevent p53 from binding to DNA and inducing cell death
[49]. It further regulates the secretion of basic fibroblast
growth factor (bFGF), which promotes angiogenesis and
mitogenesis [48]. A role in cell migration was proposed for
the osteoblast-specific factor 2 (osf-2) [50]. Its upregulation
has been demonstrated in ovarian tumors [50], neuroblasto-
mas [51], and head and neck squamous cell carcinomas
[52]. For RAMP, an increase in cell proliferation of NT2
cells has been demonstrated, and a role in increasing the
proliferation rate of human embryonal carcinoma cells was
suggested [53].
The proto-oncogene pleiomorphic adenoma gene 1
(PLAG1), which is deregulated in pleiomorphic adenomas
of the salivary glands, belongs to the family of zinc finger
proteins. It has been demonstrated to be overexpressed in
hepatoblastomas, too [54]. Interestingly, overexpression of
PLAG1 in HEK 293 cells leads to an overexpression of
cancer-related genes such as IGF-II, VEGF, and BCL2 [55].
Except for some variabilities in the gene expression
pattern of the abovementioned genes in individual tissues,
we found strong support for our microarray data by the
validation techniques used.
We also found overexpression of the protein kinase
IRAK1 within PDAC. IRAK1 acts as a activator of NF-nB
presumably through TRAF6 [56]. Activation of NF-nB has
been reported for several pancreatic cancer cell lines that
also secrete IL-1a [57]. Therefore, the overexpression of
IRAK1 might contribute to the activation NF-nB presumably
through an autocrine activation loop involving IL1-a. NF-nB
is one of the most important transcription factors implied in
cancer formation [58]. Interestingly, NF-nB regulates the
expression of proteins of the SMAD family through interac-
tion with the SMAD7 promoter, which leads to an abrogation
of the antiproliferative effects of an activated TGF-b signal-
ling pathway [59]. Therefore, as to pancreatic cancer devel-
opment, the overexpression of IRAK1might mimic the loss of
the SMAD4 tumor suppressor.
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In summary, the use of microarray analysis, in combina-
tion with tissue microdissection, is a powerful tool for iden-
tifying the changes in gene expression associated with tumor
development and progression in PDAC. Because of the
reduced heterogeneity of microdissected tissues, small
changes in gene expression can be observed and used to
generate new molecular markers and therapeutic targets.
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